Back to search results

DPTX3186 for Wnt Pathway Activated Solid Tumors

This study is testing a new drug called DPTX3186 for people with certain solid tumors where the Wnt pathway is active and other treatments are not available. This includes cancers like colorectal, gastric, lung, and triple-negative breast cancer. The main goal is to see how safe DPTX3186 is and what side effects it might cause. Researchers will also look at how the drug moves through the body and if it shows any early signs of helping to treat the cancer. You might be able to join if you are 18 or older, have a solid tumor that has activated the Wnt pathway, and have at least one measurable tumor.

Study design
This is a first-in-human study with a planned enrollment of 40 participants. It is an interventional study, meaning participants will receive the study drug.
What's involved
Participants will take DPTX3186 once daily for 4 consecutive days, followed by 3 days off, in cycles of 28 days.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for treatment-emergent adverse events and serious adverse events for up to 36 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07312903

DPTX3186 in Wnt Pathway Activated Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Dewpoint Therapeutics
~40 participants
Updated 2026-01-12 on ClinicalTrials.gov
What's tested:DPTX3186

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of treatment emergent adverse events and serious adverse events.
Measured over Up to 36 Months

Conditions

Solid Tumors

Explore related trials

Colorectal CarcinomaGastric CarcinomaLung Non-Small Cell CarcinomaSolid NeoplasmTriple-Negative Breast CarcinomaWNT Signaling Pathway BioCarta

Where it's being run

2 sites across 2 states
Texas1
Virginia1

Who to contact

Jordan Georg
[email protected]
210-580-9521
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically or cytologically confirmed solid tumor and tumor types known to be Wnt-pathway activated (such as colorectal cancer, gastric cancer, lung cancer, and triple negative breast cancer) and no other approved treatment options available.
At least one measurable target lesion as defined by RECIST v1.1 on CT, PET/CT, or MRI.
ECOG performance status of 0 or 1.
Physiological conditions that may prevent absorption of an oral medication including but not limited to colostomy and ileostomy.
Age ≥18 years (or ≥ age of majority per local regulation)
Life expectancy ≥3 months
Willing and able to comply with protocol requirements

Exclusion

Symptomatic or uncontrolled brain metastasis requiring concurrent treatment,
Another known malignancy that is progressing or requires active treatment within the last 2 years (except basal cell carcinoma, in situ cervical cancer, etc.).
Inadequate organ function
Known hypersensitivity to study drug or excipients

What this trial measures

  • Incidence of treatment emergent adverse events and serious adverse events.Up to 36 Months

    1. Outcome Measure: Incidence of Treatment Emergent Adverse-Events Measure Description: Number of subjects with treatment-emergent adverse events (TEAEs) Time Frame: up to 36 months 2. Outcome Measure: Incidence of Serious Adverse Events Measure Description: Number of subjects with serious adverse events (SAEs) Time Frame: up to 36 months